Quick Read
- The ‘Cicada’ variant (BA.3.2) features 70-75 spike protein mutations, making it genetically distinct from currently circulating Omicron subvariants.
- While present in at least 25 U.S. states and several countries, the variant is not yet dominant and has not been linked to an increase in disease severity.
- Health officials maintain that current vaccines, while potentially less effective against this specific strain in lab settings, remain essential for preventing severe outcomes.
WASHINGTON (Azat TV) – A highly mutated lineage of the SARS-CoV-2 virus, colloquially nicknamed the “Cicada” variant (BA.3.2), is currently under intense monitoring by public health agencies after emerging from relative dormancy to spread across 25 U.S. states. First identified in South Africa in late 2024, the variant has recently gained traction in clinical and wastewater samples, raising questions about its potential to evade existing immune protection.
Understanding the ‘Cicada’ BA.3.2 Mutation
The variant earned its name from T. Ryan Gregory, an evolutionary biology professor at the University of Guelph, due to its behavior of remaining “underground” for years—descending from the BA.3 lineage that saw little activity since 2022—before resurfacing as a significant genetic outlier. According to the Centers for Disease Control and Prevention (CDC), the Cicada variant is characterized by a high number of mutations in its spike protein, estimated between 70 and 75. This genetic profile makes it distinct from dominant strains like Nimbus and XFG, and initial laboratory studies suggest these modifications may allow the virus to escape neutralizing antibodies more effectively than previous Omicron descendants.
Clinical Significance and Symptoms
While the variant’s genetic makeup is notable, health experts emphasize that it does not currently appear to produce a more severe clinical disease profile than existing COVID-19 strains. Patients infected with BA.3.2 typically report symptoms consistent with previous variants, including sore throat, fever, cough, fatigue, and headache. Some reports indicate a potential for gastrointestinal symptoms, such as nausea or vomiting, though these remain within the spectrum of common respiratory illness presentations. Epidemiologists, including Dr. Syra Madad, note that distinguishing between Cicada and other circulating viruses like influenza or RSV remains difficult without standardized testing.
Vaccination and Public Health Response
As of March 2026, BA.3.2 does not account for a dominant share of nationwide cases, though wastewater monitoring data from programs like WastewaterSCAN indicate a steady increase in detection. Regarding vaccine efficacy, infectious disease experts suggest that while current vaccines—designed primarily for the JN.1 lineage—may show reduced laboratory effectiveness against the heavily mutated spike protein of the Cicada variant, they are still expected to provide robust protection against severe illness, hospitalization, and death. Public health guidance remains consistent: individuals are encouraged to maintain updated vaccination schedules, particularly those at high risk for complications, and to utilize diagnostic testing to guide recovery and isolation protocols.
The emergence of the Cicada variant highlights the ongoing evolutionary pressure on SARS-CoV-2 to bypass population immunity, yet the lack of a corresponding spike in hospitalization rates suggests that current vaccine-mediated and hybrid immunity remains a critical barrier against a return to pandemic-level severity.